Philogen Overview

  • Year Founded
  • 1996

Year Founded

  • Status
  • Public

  • Employees
  • 230

Employees

  • Stock Symbol
  • PHIL

Stock Symbol

  • Share Price
  • $23.74
  • (As of Thursday Closing)

Philogen General Information

Description

Philogen SpA is a biotechnology company engaged in the research and development of antibody-based therapeutics for the treatment of cancer and chronic inflammatory diseases. The company's pipeline includes products such as Nidlegy, Fibromun, Darleukin, and Dekavil, targeting oncology and other serious conditions. Geographically, the company operates in the European Union, Switzerland, and the United States of America.

Contact Information

Website
www.philogen.com
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • Via Bellaria, 35
  • 53018 Sovicille
  • Italy
+39 0577
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
MIL
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Via Bellaria, 35
  • 53018 Sovicille
  • Italy
+39 0577

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Philogen Stock Performance

As of 12-Nov-2026, Philogen’s stock price is $23.74. Its current market cap is $955M with 40.2M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$23.74 $23.45 $22.77 - $29.64 $955M 40.2M 17.2K $6.51

Philogen Financials Summary

As of 30-Jun-2026, Philogen has a trailing 12-month revenue of $363M.

In Thousands,
USD 		TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 645,650 1,000,597 766,451 733,747
Revenue 362,642 354,561 80,071 25,028
EBITDA 301,273 297,062 48,031 (2,581)
Net Income 262,442 259,076 49,010 (6,667)
Total Assets 451,622 513,694 175,286 131,841
Total Debt 13,048 12,783 11,974 13,375
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Philogen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Philogen‘s full profile, request access.

Request a free trial

Philogen Patents

  • 576

    Total Documents Applications and Grants

  • Total Patents Families

  • 245

    Granted

  • 29

    Pending

  • Expiring in next 12 mo

Philogen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026195461-A1 High-affinity human anti-acp3 antibodies for diagnostic and therapeutic use Pending 19-Mar-2025
WO-2026162289-A1 High-affinity cross-reactive anti-psma antibodies Pending 29-Jan-2025
WO-2026003203-A1 Combination of an immunocytokine comprising targeted il2 and a jak inhibitor Pending 27-Jun-2024
AU-2025223040-A1 Methods for treating melanoma Pending 15-Feb-2024
WO-2025172582-A1 Methods for treating melanoma Pending 15-Feb-2024 A61K47/6813
To view Philogen’s complete patent history, request access »

Philogen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Philogen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Philogen‘s full profile, request access.

Request a free trial

Ready to get started?

Request a free trial

Philogen ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

34.83 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,585

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Philogen’s complete esg history, request access »

Philogen FAQs

  • When was Philogen founded?

    Philogen was founded in 1996.

  • Where is Philogen headquartered?

    Philogen is headquartered in Sovicille, Italy.

  • What is the size of Philogen?

    Philogen has 230 total employees.

  • What industry is Philogen in?

    Philogen’s primary industry is Drug Discovery.

  • Is Philogen a private or public company?

    Philogen is a Public company.

  • What is Philogen’s stock symbol?

    The ticker symbol for Philogen is PHIL.

  • What is the current stock price of Philogen?

    As of 12-Nov-2026 the stock price of Philogen is $23.74.

  • What is the current market cap of Philogen?

    The current market capitalization of Philogen is $955M.

  • What is Philogen’s current revenue?

    The trailing twelve month revenue for Philogen is $363M.

  • What is Philogen’s annual earnings per share (EPS)?

    Philogen’s EPS for 12 months was $6.51.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process